Graph takes few seconds to load...
Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types.
Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform.
The company’s ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients.
It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology. Atreca, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
| Annual Data | Millions of US $ except per share data |
|---|
| Cash on hand |
| Receivables |
| Inventory |
| Pre-Paid Expenses |
| Other Current Assets |
| Total Current Assets |
| Property, Plant, And Equipment |
| Long-Term Investments |
| Goodwill And Intangible Assets |
| Other Long-Term Assets |
| Total Long-Term Assets |
| Total Assets |
| Total Current Liabilities |
| Long Term Debt |
| Other Non-Current Liabilities |
| Total Long Term Liabilities |
| Total Liabilities |
| Common Stock Net |
| Retained Earnings (Accumulated Deficit) |
| Comprehensive Income |
| Other Share Holders Equity |
| Share Holder Equity |
| Total Liabilities And Share Holders Equity |
